Double-blind,Controlled,Randomized Phase 2 Study of Efficacy,Safety,Pharmacokinetics& Pharmacodynamics of Daily Oral Administration of MAP4343 During 6 Weeks in Antidepressant Non-responders Patients Experiencing a Major Depressive Episode
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Pregnenolone methyl ether (Primary)
- Indications Depressive disorders
- Focus Therapeutic Use
- Sponsors Mapreg
Most Recent Events
- 30 Sep 2024 Status changed from recruiting to active, no longer recruiting.
- 03 Apr 2024 Planned End Date changed from 1 Dec 2023 to 1 Mar 2025.
- 03 Apr 2024 Planned primary completion date changed from 1 Sep 2023 to 1 Dec 2024.